Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Use of Routine Environmental Monitoring Data to Establish a Dose-based Compliance System for a Low-level Radioactive Waste Disposal Site.

Rood AS, Grogan HA, Mohler HJ, Rocco JR, Caffrey EA, Mangini C, Cartwright J, Matthews T, Shaw C, Packard ME, Till JE.

Health Phys. 2019 Nov 6. doi: 10.1097/HP.0000000000001116. [Epub ahead of print]

PMID:
31703016
2.

Reconstruction of atmospheric concentrations of enriched uranium from the former Apollo facility, Apollo, Pennsylvania, USA.

Rood AS, Grogan HA, Mohler HJ, Meyer KR, Voillequé PG, Till JE.

J Environ Radioact. 2019 Oct 16;211:106045. doi: 10.1016/j.jenvrad.2019.106045. [Epub ahead of print]

PMID:
31629194
3.

Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience.

Lüscher B, Möhler H.

F1000Res. 2019 May 29;8. pii: F1000 Faculty Rev-751. doi: 10.12688/f1000research.18758.1. eCollection 2019. Review.

4.

Asbestos Exposure and Mesothelioma Mortality among Atomic Veterans.

Till JE, Beck HL, Boice JD, Mohler HJ, Mumma MT, Aanenson JW, Grogan HA.

Int J Radiat Biol. 2018 Dec 4:1-15. doi: 10.1080/09553002.2018.1551641. [Epub ahead of print]

PMID:
30513236
5.

Dosimetry Associated with Veterans who Participated in Nuclear Weapons Testing.

Till JE, Beck HL, Aanenson JW, Grogan HA, Mohler HJ, Mohler SS, Voillequé PG.

Int J Radiat Biol. 2018 Dec 4:1-30. doi: 10.1080/09553002.2018.1551639. [Epub ahead of print]

PMID:
30513229
6.

Impact on GABA systems in monogenetic developmental CNS disorders: Clues to symptomatic treatment.

Benke D, Möhler H.

Neuropharmacology. 2018 Jul 1;136(Pt A):46-55. doi: 10.1016/j.neuropharm.2017.07.030. Epub 2017 Jul 29. Review.

PMID:
28764992
7.

The immunohistochemical distribution of the GABAA receptor α1, α2, α3, β2/3 and γ2 subunits in the human thalamus.

Waldvogel HJ, Munkle M, van Roon-Mom W, Mohler H, Faull RLM.

J Chem Neuroanat. 2017 Jul;82:39-55. doi: 10.1016/j.jchemneu.2017.04.006. Epub 2017 Apr 23.

PMID:
28445782
8.

Disinhibition, an emerging pharmacology of learning and memory.

Möhler H, Rudolph U.

F1000Res. 2017 Feb 3;6. pii: F1000 Faculty Rev-101. doi: 10.12688/f1000research.9947.1. eCollection 2017. Review.

9.

Red Bone Marrow and Male Breast Doses for a Cohort of Atomic Veterans.

Beck HL, Till JE, Grogan HA, Aanenson JW, Mohler HJ, Mohler SS, Voillequé PG.

Radiat Res. 2017 Feb;187(2):221-228. doi: 10.1667/RR14458.1. Epub 2017 Jan 30.

PMID:
28135126
10.

The legacy of the benzodiazepine receptor: from flumazenil to enhancing cognition in Down syndrome and social interaction in autism.

Möhler H.

Adv Pharmacol. 2015;72:1-36. doi: 10.1016/bs.apha.2014.10.008. Epub 2014 Dec 30. Review.

PMID:
25600365
11.

Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (review).

Möhler H, Pfirrmann RW, Frei K.

Int J Oncol. 2014 Oct;45(4):1329-36. doi: 10.3892/ijo.2014.2566. Epub 2014 Jul 28. Review.

12.

Military participants at U.S. Atmospheric nuclear weapons testing--methodology for estimating dose and uncertainty.

Till JE, Beck HL, Aanenson JW, Grogan HA, Mohler HJ, Mohler SS, Voillequé PG.

Radiat Res. 2014 May;181(5):471-84. doi: 10.1667/RR13597.1. Epub 2014 Apr 23.

13.

Endogenous benzodiazepine site peptide ligands operating bidirectionally in vivo in neurogenesis and thalamic oscillations.

Möhler H.

Neurochem Res. 2014 Jun;39(6):1032-6. doi: 10.1007/s11064-014-1303-5. Epub 2014 Apr 9. Review.

PMID:
24715673
14.

GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism.

Rudolph U, Möhler H.

Annu Rev Pharmacol Toxicol. 2014;54:483-507. doi: 10.1146/annurev-pharmtox-011613-135947. Epub 2013 Oct 23. Review.

15.

Cognitive enhancement by pharmacological and behavioral interventions: the murine Down syndrome model.

Möhler H.

Biochem Pharmacol. 2012 Oct 15;84(8):994-9. doi: 10.1016/j.bcp.2012.06.028. Epub 2012 Aug 8.

PMID:
22898099
16.

An integrated approach to data management, risk assessment, and decision making.

Till JE, Grogan HA, Mohler HJ, Rocco JR, Rood AS, Mohler SS.

Health Phys. 2012 Apr;102(4):367-77. doi: 10.1097/HP.0b013e318239c022.

PMID:
22378197
17.

RACER: dynamic use of environmental measurement data for decision making and communication.

Mohler HJ, Grogan HA, Rocco JR, Kiefer RF, Till JE.

Health Phys. 2012 Feb;102 Suppl 1:S13-21. doi: 10.1097/HP.0b013e318231aa62.

PMID:
22249468
18.

The GABA system in anxiety and depression and its therapeutic potential.

Möhler H.

Neuropharmacology. 2012 Jan;62(1):42-53. doi: 10.1016/j.neuropharm.2011.08.040. Epub 2011 Sep 1. Review.

PMID:
21889518
19.

Examining the sex- and circadian dependency of a learning phenotype in mice with glycine transporter 1 deletion in two Pavlovian conditioning paradigms.

Dubroqua S, Boison D, Feldon J, Möhler H, Yee BK.

Neurobiol Learn Mem. 2011 Sep;96(2):218-29. doi: 10.1016/j.nlm.2011.04.015. Epub 2011 May 10.

20.

Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition.

Möhler H, Boison D, Singer P, Feldon J, Pauly-Evers M, Yee BK.

Biochem Pharmacol. 2011 May 1;81(9):1065-77. doi: 10.1016/j.bcp.2011.02.003. Epub 2011 Feb 17.

PMID:
21333635
21.

Impacts of forebrain neuronal glycine transporter 1 disruption in the senescent brain: evidence for age-dependent phenotypes in Pavlovian learning.

Dubroqua S, Singer P, Boison D, Feldon J, Möhler H, Yee BK.

Behav Neurosci. 2010 Dec;124(6):839-50. doi: 10.1037/a0021556.

22.

The rise of a new GABA pharmacology.

Möhler H.

Neuropharmacology. 2011 Jun;60(7-8):1042-9. doi: 10.1016/j.neuropharm.2010.10.020. Epub 2010 Oct 28. Review.

PMID:
21035473
23.

Modulation of sensorimotor gating in prepulse inhibition by conditional brain glycine transporter 1 deletion in mice.

Singer P, Boison D, Möhler H, Feldon J, Yee BK.

Eur Neuropsychopharmacol. 2011 May;21(5):401-13. doi: 10.1016/j.euroneuro.2010.06.014. Epub 2010 Jul 19.

24.

Highly potent modulation of GABA(A) receptors by valerenic acid derivatives.

Kopp S, Baur R, Sigel E, Möhler H, Altmann KH.

ChemMedChem. 2010 May 3;5(5):678-81. doi: 10.1002/cmdc.201000062. No abstract available.

PMID:
20235267
25.

Differential localization of gamma-aminobutyric acid type A and glycine receptor subunits and gephyrin in the human pons, medulla oblongata and uppermost cervical segment of the spinal cord: an immunohistochemical study.

Waldvogel HJ, Baer K, Eady E, Allen KL, Gilbert RT, Mohler H, Rees MI, Nicholson LF, Faull RL.

J Comp Neurol. 2010 Feb 1;518(3):305-28. doi: 10.1002/cne.22212.

PMID:
19950251
26.

Role of GABAA receptors in cognition.

Möhler H.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1328-33. doi: 10.1042/BST0371328.

PMID:
19909270
27.

Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: enhanced cognitive adaptability?

Singer P, Boison D, Möhler H, Feldon J, Yee BK.

Behav Neurosci. 2009 Oct;123(5):1012-27. doi: 10.1037/a0016676.

28.

GABAergic analgesia: new insights from mutant mice and subtype-selective agonists.

Zeilhofer HU, Möhler H, Di Lio A.

Trends Pharmacol Sci. 2009 Aug;30(8):397-402. doi: 10.1016/j.tips.2009.05.007. Epub 2009 Jul 16.

PMID:
19616317
29.

The alpha5(H105R) mutation impairs alpha5 selective binding properties by altered positioning of the alpha5 subunit in GABAA receptors containing two distinct types of alpha subunits.

Balic E, Rudolph U, Fritschy JM, Mohler H, Benke D.

J Neurochem. 2009 Jul;110(1):244-54. doi: 10.1111/j.1471-4159.2009.06119.x. Epub 2009 Apr 27.

30.

Altered mnemonic functions and resistance to N-METHYL-d-Aspartate receptor antagonism by forebrain conditional knockout of glycine transporter 1.

Singer P, Yee BK, Feldon J, Iwasato T, Itohara S, Grampp T, Prenosil G, Benke D, Möhler H, Boison D.

Neuroscience. 2009 Jun 30;161(2):635-54. doi: 10.1016/j.neuroscience.2009.03.056. Epub 2009 Mar 28.

31.

Research in anxiety disorders: from the bench to the bedside.

Garner M, Möhler H, Stein DJ, Mueggler T, Baldwin DS.

Eur Neuropsychopharmacol. 2009 Jun;19(6):381-90. doi: 10.1016/j.euroneuro.2009.01.011. Epub 2009 Mar 26.

PMID:
19327970
32.

The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death.

Stendel R, Biefer HR, Dékány GM, Kubota H, Münz C, Wang S, Mohler H, Yonekawa Y, Frei K.

Autophagy. 2009 Feb;5(2):194-210. Epub 2009 Feb 13.

PMID:
19066471
33.

GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts.

Benke D, Barberis A, Kopp S, Altmann KH, Schubiger M, Vogt KE, Rudolph U, Möhler H.

Neuropharmacology. 2009 Jan;56(1):174-81. doi: 10.1016/j.neuropharm.2008.06.013. Epub 2008 Jun 17.

34.

Regulation of cognition and symptoms of psychosis: focus on GABA(A) receptors and glycine transporter 1.

Möhler H, Rudolph U, Boison D, Singer P, Feldon J, Yee BK.

Pharmacol Biochem Behav. 2008 Jul;90(1):58-64. doi: 10.1016/j.pbb.2008.03.003. Epub 2008 Mar 13. Review.

PMID:
18455219
35.

Reversal of pathological pain through specific spinal GABAA receptor subtypes.

Knabl J, Witschi R, Hösl K, Reinold H, Zeilhofer UB, Ahmadi S, Brockhaus J, Sergejeva M, Hess A, Brune K, Fritschy JM, Rudolph U, Möhler H, Zeilhofer HU.

Nature. 2008 Jan 17;451(7176):330-4. doi: 10.1038/nature06493.

PMID:
18202657
36.

Differential localization of GABAA receptor subunits within the substantia nigra of the human brain: an immunohistochemical study.

Waldvogel HJ, Baer K, Gai WP, Gilbert RT, Rees MI, Mohler H, Faull RL.

J Comp Neurol. 2008 Feb 20;506(6):912-29.

PMID:
18085588
37.

Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons.

Singer P, Boison D, Möhler H, Feldon J, Yee BK.

Behav Neurosci. 2007 Oct;121(5):815-25.

PMID:
17907814
38.

Hippocampal alpha 5 subunit-containing GABA A receptors are involved in the development of the latent inhibition effect.

Gerdjikov TV, Rudolph U, Keist R, Möhler H, Feldon J, Yee BK.

Neurobiol Learn Mem. 2008 Feb;89(2):87-94. Epub 2007 Jul 16.

PMID:
17638582
39.

Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients.

Stendel R, Scheurer L, Schlatterer K, Stalder U, Pfirrmann RW, Fiss I, Möhler H, Bigler L.

Clin Pharmacokinet. 2007;46(6):513-24.

PMID:
17518510
40.

GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states.

Earnheart JC, Schweizer C, Crestani F, Iwasato T, Itohara S, Mohler H, Lüscher B.

J Neurosci. 2007 Apr 4;27(14):3845-54.

41.

Molecular regulation of cognitive functions and developmental plasticity: impact of GABAA receptors.

Möhler H.

J Neurochem. 2007 Jul;102(1):1-12. Epub 2007 Mar 23. Review.

42.

Benzodiazepine binding to GABA(A) receptors.

Benke D, Möhler H.

Curr Protoc Pharmacol. 2006 Dec;Chapter 1:Unit1.16. doi: 10.1002/0471141755.ph0116s35.

PMID:
22294164
43.

GABAA receptors in central nervous system disease: anxiety, epilepsy, and insomnia.

Möhler H.

J Recept Signal Transduct Res. 2006;26(5-6):731-40. Review.

PMID:
17118808
44.

GABA(A) receptor diversity and pharmacology.

Möhler H.

Cell Tissue Res. 2006 Nov;326(2):505-16. Epub 2006 Aug 26. Review.

45.

Pathophysiology and pharmacology of GABA(A) receptors.

Möhler H, Fritschy JM, Vogt K, Crestani F, Rudolph U.

Handb Exp Pharmacol. 2005;(169):225-47.

PMID:
16594261
46.

Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile.

Yee BK, Balic E, Singer P, Schwerdel C, Grampp T, Gabernet L, Knuesel I, Benke D, Feldon J, Mohler H, Boison D.

J Neurosci. 2006 Mar 22;26(12):3169-81.

47.

GABA-based therapeutic approaches: GABAA receptor subtype functions.

Rudolph U, Möhler H.

Curr Opin Pharmacol. 2006 Feb;6(1):18-23. Epub 2005 Dec 22. Review.

PMID:
16376150
48.

A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction.

Yee BK, Keist R, von Boehmer L, Studer R, Benke D, Hagenbuch N, Dong Y, Malenka RC, Fritschy JM, Bluethmann H, Feldon J, Möhler H, Rudolph U.

Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17154-9. Epub 2005 Nov 11.

49.

Subtype-selective interaction with the transcription factor CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) regulates cell surface expression of GABA(B) receptors.

Sauter K, Grampp T, Fritschy JM, Kaupmann K, Bettler B, Mohler H, Benke D.

J Biol Chem. 2005 Sep 30;280(39):33566-72. Epub 2005 Aug 4.

50.

Supplemental Content

Loading ...
Support Center